title: [Calcium carbasalate-metoclopramide combination versus dihydroergotamine in the treatment of migraine attacks].
abstract: In this randomised, double-blind, cross-over study the association of calcium carbasalate+metoclopramide was compared with oral dihydroergotamine mesilate in the treatment of migraine attacks. 155 patients suffering from migraine, with or without aura were analysed; the main efficacy criteria being the evolution of the headache intensity: disappearance of headache 2 hours after administration or incomplete improvement (severe to moderate headache reduced to slight headache). There was a significantly greater reduction in headache intensity following administration of CSC-METO (p < 0.001), the percentage of patients showing recovery or improvement two hours after administration being 64.5% with CSC-METO compared to 43.5% with DHE. A significantly more marked improvement following administration of CSC-METO was also observed for nausea, photophobia, phonophobia, use of analgesic treatment, impact on normal activities and overall assessment by the patient and physician. The frequency of undesirable events was weak and identical for both treatments.
authors: Service de Médecine Interne IV, Centre Hospitalier Louis-Mourier, COLOMBES, France.
authors: A
authors: A
authors: Pradalier
authors: A
authors: A
authors: Guérard des Lauriers
authors: F
authors: F
authors: Scheck
authors: P
authors: P
authors: Peraudeau
authors: J P
authors: JP
authors: Lacoste
authors: F
authors: F
authors: Cajfinger
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D004087:Dihydroergotamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D010919:Placebos
chemical_list: D018712:Analgesics, Non-Narcotic; D018492:Dopamine Antagonists; D010919:Placebos; D004087:Dihydroergotamine; D008787:Metoclopramide
vernacular_title: Association carbasalate calcique-métoclopramide versus di-hydroergotamine dans le traitement de la crise de migraine.